{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:47:17Z","timestamp":1791388037824,"version":"4.3.3"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023331","name":"LEO Pharma A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaad.2025.03.008","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:07:10Z","timestamp":1741694830000},"page":"95-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials"],"prefix":"10.1016","volume":"93","author":[{"given":"Melinda","family":"Gooderham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Molin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Worm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Cr\u00e9py","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Stingeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Schuttelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Serra-Baldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherry Lou","family":"Balita-Crisostomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Louise","family":"\u00d8sterdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Plohberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Agner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.03.008_bib1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/DER.0000000000000598","article-title":"Impact of atopic dermatitis and chronic hand eczema on quality of life compared with other chronic diseases","volume":"31","author":"Capucci","year":"2020","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaad.2025.03.008_bib2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/cod.14035","article-title":"Guidelines for diagnosis, prevention, and treatment of hand eczema","volume":"86","author":"Thyssen","year":"2022","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaad.2025.03.008_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/cod.13459","article-title":"Quality of life, treatment satisfaction, and adherence to treatment in patients with vesicular hand eczema: a cross-sectional study","volume":"82","author":"Politiek","year":"2020","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaad.2025.03.008_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/cod.12366","article-title":"Quality of life, anxiety, depression and obsessive-compulsive tendencies in patients with chronic hand eczema","volume":"72","author":"Kouris","year":"2015","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaad.2025.03.008_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/cod.13804","article-title":"Prevalence, incidence, and severity of hand eczema in the general population - A systematic review and meta-analysis","volume":"84","author":"Quaade","year":"2021","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaad.2025.03.008_bib6","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2147\/TCRM.S292504","article-title":"Drugs for the treatment of chronic hand eczema: successes and key challenges","volume":"16","author":"Dubin","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jaad.2025.03.008_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12840","article-title":"Current and emerging therapies for hand eczema","volume":"32","author":"Lee","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2025.03.008_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdin.2023.11.004","article-title":"Adverse events from topical corticosteroid use in chronic hand eczema\u2014findings from the Danish Skin Cohort","volume":"14","author":"Egeberg","year":"2024","journal-title":"JAAD Int"},{"key":"10.1016\/j.jaad.2025.03.008_bib9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40257-021-00623-6","article-title":"Steroid phobia: a review of prevalence, risk factors, and interventions","volume":"22","author":"Contento","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2025.03.008_bib10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/12034754231188325","article-title":"A review of existing and new treatments for the management of hand eczema","volume":"27","author":"Ho","year":"2023","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2025.03.008_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0536.2007.01305.x","article-title":"Clinical characteristics and consequences of hand eczema\u2014an 8-year follow-up study of a population-based twin cohort","volume":"58","author":"Lerbaek","year":"2008","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaad.2025.03.008_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","article-title":"Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo","volume":"64","author":"Tanimoto","year":"2015","journal-title":"Inflamm Res"},{"key":"10.1016\/j.jaad.2025.03.008_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","article-title":"Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials","volume":"404","author":"Bissonnette","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2025.03.008_bib14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-2133.2004.06305.x","article-title":"The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability","volume":"152","author":"Held","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.03.008_bib15","unstructured":"ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use: The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment for Non-Life Threatening Conditions (E1); 1995."},{"key":"10.1016\/j.jaad.2025.03.008_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00403-024-02818-3","article-title":"Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity","volume":"316","author":"Silverberg","year":"2024","journal-title":"Arch Dermatol Res"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225004244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225004244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T02:50:16Z","timestamp":1766112616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225004244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0190962225004244"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.03.008","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}